Skip to main content
. 2020 Jan 23;25(3):484. doi: 10.3390/molecules25030484

Figure 1.

Figure 1

Schematic presentation of the delivery of Doxorubicin to tumor lesions via assembled nanoparticles (B) compared with non-specific administration of Dox (A). When the Dox is assembled into nanoparticles, the tumor targetability of the Dox can be increased by leveraging the EPR effects. Simultaneously, the side effects will be decreased. Also, the nanoformulation Dox will show a longer blood circulation time than free-Dox.